Avidity Partners Management’s Tango Therapeutics TNGX Stock Holding History

Avidity Partners Management’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-813,700	Closed	-$2.95M	–	103
2022 Q3	$2.95M	Buy	813,700 +60	+0%	+$256	0.06%	85
2022 Q2	$3.69M	Buy	813,640 +92,640	+13%	+$561K	0.08%	66
2022 Q1	$5.46M	Buy	721,000 +16,000	+2%	+$139K	0.11%	69
2021 Q4	$7.71M	Buy	705,000 +405,000	+135%	+$4.87M	0.16%	66
2021 Q3	$3.88M	Hold	300,000	–	–	0.09%	93
2021 Q2	$3.41M	Hold	300,000	–	–	0.09%	101
2021 Q1	$3.34M	Hold	300,000	–	–	0.09%	90
2020 Q4	$3.43M	Hold	300,000	–	–	0.11%	86
2020 Q3	$3.11M	Buy	+300,000	New	+$3.06M	0.14%	61

Other funds holding TNGX

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Avidity Partners Management's TNGX Position: Q4 2022 in Review

Avidity Partners Management sold out of Tango Therapeutics (TNGX) in Q4 2022, closing a stake of 813,700 shares — an estimated $2.95M sold.

Avidity Partners Management first reported a position in TNGX in Q3 2020 and held it in 9 quarters. The position peaked at $7.71M in Q4 2021. 82 funds tracked by Wall St. Rank hold TNGX as of Q4 2022.

Avidity Partners Management reported no remaining Tango Therapeutics position as of Q4 2022 after selling out during the quarter.
Avidity Partners Management sold 813,700 Tango Therapeutics shares in Q4 2022, an estimated $2.95M.
Avidity Partners Management first reported a position in Tango Therapeutics in Q3 2020 and held it in 9 quarters.
Avidity Partners Management's Tango Therapeutics position peaked at $7.71M in Q4 2021.
82 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2022.

Based on Avidity Partners Management's 13F filing for Q4 2022, filed 14 Feb 2023.